FOLH1 and prostate carcinoma: Future research could explore the effectivenessof giving four cycles of 7.5 MBq of activity.158 A clinical trial is currently being conducted to evaluateboth the safety and effectiveness of [64Cu]-SarbisPSMAand [67Cu]-SarbisPSMA as a theranostic agent in PSMA-expressingmetastatic castrate-resistant prostate cancer (clinical trial ID NCT04868604).